A late-stage drug development company

Protecting the intestinal barrier in celiac disease.

Advancing an investigational oral therapy designed to protect against gluten-induced injury, alongside the gluten-free diet.

About Us

A late-stage drug development company focused on celiac disease

Interlude Biopharma is a late-stage drug development company focused on celiac disease, a chronic, auto-immune condition affecting approximately 1% of the U.S. population. Our lead product candidate, larazotide acetate, is an investigational, first-in-class oral tight junction regulator designed to help protect the intestinal barrier against gluten-induced injury by acting locally in the gut, upstream of immune activation, as an adjunct to a gluten-free diet. Larazotide acetate has received FDA Fast Track designation for the treatment of celiac disease and is advancing toward a prevention-focused Phase 3 clinical trial.

Explore our science
Illustration comparing healthy villi of the small intestine with the flattened, damaged villi seen in celiac disease
Villi are the tiny, finger-like projections that make up the lining of the small intestine. In celiac disease they become damaged and flattened.

About one in a hundred Americans, an estimated 3.5 million people, live with celiac disease. There is no approved therapy.

Larazotide acetate has received FDA Fast Track designation for the treatment of celiac disease.

Interlude began at home.

When their young daughter was diagnosed with celiac disease, Co-Founders Mark and Julie Paresky learned that even the most careful gluten-free diet cannot fully protect against accidental gluten exposure. School cafeterias, summer camp, and birthday parties became all-consuming concerns, and shared serving utensils at family dinners raised fears of cross-contamination. An accidental exposure meant missed school days and fear for her growth, development, and long-term health.

Looking for answers, they turned to Dr. Alessio Fasano, a world-renowned expert in celiac disease and the scientist who discovered larazotide acetate. Through him, they learned about this investigational therapy and its successful Phase 2b real-world proof-of-concept clinical results.

That experience led them to acquire larazotide acetate, a late-stage investigational therapy designed to help protect the intestinal barrier, and to co-found Interlude Biopharma, a company dedicated to advancing new treatment options for people living with celiac disease. Building on more than a decade of prior clinical research, Interlude is now preparing to initiate a prevention-focused Phase 3 clinical trial evaluating larazotide acetate’s potential to help protect against the effects of gluten exposure in people with celiac disease.

Meet our team
Mission

To transform the treatment of celiac disease by shifting the focus from managing damage to preventing it at the intestinal barrier. The company’s efforts begin with celiac disease, for which no approved therapies currently exist.

Vision

Freedom to eat and confidence to live: a future in which people living with celiac disease are protected from harm before it begins.

Why “Interlude”

An interlude is the space between: the passage that connects two parts of a larger piece. In the gut, that space is the tight junction between intestinal cells. It is also the interval between gluten exposure and the onset of immune-mediated injury. Both are where larazotide acetate is designed to act, before damage occurs.

Where we are

A prevention-focused Phase 3 trial, CeD-LA-3002, is expected to enroll its first participant in the first quarter of 2027.

About the trial